1. Home
  2. NBBK vs PHAR Comparison

NBBK vs PHAR Comparison

Compare NBBK & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

NBBK

NB Bancorp Inc.

HOLD

Current Price

$22.56

Market Cap

926.5M

Sector

N/A

ML Signal

HOLD

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$10.50

Market Cap

793.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NBBK
PHAR
Founded
1892
1988
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
926.5M
793.4M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
NBBK
PHAR
Price
$22.56
$10.50
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$23.50
$38.33
AVG Volume (30 Days)
239.2K
17.0K
Earning Date
04-22-2026
05-07-2026
Dividend Yield
1.43%
N/A
EPS Growth
25.23
N/A
EPS
0.90
N/A
Revenue
N/A
N/A
Revenue This Year
$45.15
$10.04
Revenue Next Year
$4.18
$2.51
P/E Ratio
$25.18
$3,041.22
Revenue Growth
N/A
N/A
52 Week Low
$16.84
$9.62
52 Week High
$23.47
$21.34

Technical Indicators

Market Signals
Indicator
NBBK
PHAR
Relative Strength Index (RSI) 48.16 41.69
Support Level $22.28 $9.62
Resistance Level $22.71 $13.51
Average True Range (ATR) 0.43 0.37
MACD -0.04 -0.03
Stochastic Oscillator 40.94 24.76

Price Performance

Historical Comparison
NBBK
PHAR

About NBBK NB Bancorp Inc.

NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.

About PHAR Pharming Group N.V.

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Share on Social Networks: